MoonLake Immunotherapeutics/$MLTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
- Ticker
- $MLTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 130
- Headquarters
- Zug, Switzerland
- Website
- www.moonlaketx.com
MLTX Metrics
BasicAdvanced
$1B
-
-$3.81
1.08
-
Price and volume
Market cap
$1B
Beta
1.08
52-week high
$23.29
52-week low
$9.46
Average daily volume
1.9M
Financial strength
Current ratio
12.558
Quick ratio
11.975
Long term debt to equity
0.234
Total debt to equity
0.237
Interest coverage (TTM)
-26.59%
Profitability
EBITDA (TTM)
-265.099
Effective tax rate (TTM)
-0.41%
Management effectiveness
Return on assets (TTM)
-32.44%
Return on equity (TTM)
-67.47%
Valuation
Price to book
2.3
Price to tangible book (TTM)
2.3
Price to free cash flow (TTM)
-3.617
Free cash flow yield (TTM)
-27.65%
Free cash flow per share (TTM)
-3.257
Growth
Earnings per share change (TTM)
36.65%
3-year earnings per share growth (CAGR)
48.70%
What the Analysts think about MLTX
Analyst ratings (Buy, Hold, Sell) for MoonLake Immunotherapeutics stock.
Analyst projections of the future price of MoonLake Immunotherapeutics stock.
Bulls say / Bears say
In HS, sonelokimab’s Phase 3 data showed durable responses: 67.2% of patients achieved HiSCR75 at Week 52, while 26% reached complete inflammatory remission. Quality-of-life and pain measures also improved, with no new safety signal reported. (MoonLake Immunotherapeutics)
MoonLake submitted its US application for sonelokimab in adult and adolescent HS on 30 September, moving the lead programme into FDA review. The proposed application covers patients aged 12 and over, though acceptance and the review timetable are still pending. (U.S. Securities and Exchange Commission)
Sonelokimab also met the reported Week 16 endpoints in the Phase 3 IZAR-1 psoriatic arthritis trial. The results included a 42.1% ACR50 response and improvements across skin symptoms, disease activity and physical function, giving MoonLake a potential second major indication. (U.S. Securities and Exchange Commission)
The HS Phase 3 results were not uniformly strong at the primary readout: VELA-2 narrowly missed statistical significance for its Week 16 primary endpoint under the composite strategy (p=0.053). That makes the programme’s pivotal evidence less consistent, despite the later positive durability data. (MoonLake Immunotherapeutics)
The IZAR-1 PsA headline results do not yet show how much benefit sonelokimab delivered versus placebo, because comparative results remain blinded. Reuters also reported investor concern about how the drug would compare with approved rival Bimzelx, leaving its competitive edge uncertain. (SRN News)
MoonLake has no approved product and remains dependent on sonelokimab, while reporting a $131.5 million net loss in the first half of 2026. Its cash runway to mid-2028 gives it time, but continued development and launch spending could still make further funding necessary if approval or commercial uptake disappoints. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
MLTX Financial Performance
Revenues and expenses
MLTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
MLTX News
AllArticlesVideos
Funds containing MLTX
Fund name | Fund size | $MLTX weighting |
|---|---|---|
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.